6XP Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.81 |
| 52 Week High | SEK 7.63 |
| 52 Week Low | SEK 3.66 |
| Beta | 0.85 |
| 1 Month Change | 2.28% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.3% | 1.9% | 1.4% |
| 1Y | n/a | -9.8% | 9.1% |
Return vs Industry: Insufficient data to determine how 6XP performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6XP performed against the German Market.
Price Volatility
| 6XP volatility | |
|---|---|
| 6XP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6XP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6XP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 24 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
Xspray Pharma AB (publ) Fundamentals Summary
| 6XP fundamental statistics | |
|---|---|
| Market cap | €139.06m |
| Earnings (TTM) | -€22.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs 6XP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XP income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 258.05m |
| Earnings | -SEK 258.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -6.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6XP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 23:45 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xspray Pharma AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dan Akschuti | Pareto Securities |
| Filip Einarsson | Redeye |